WHO: 'Premature,' 'unrealistic' COVID-19 will end soon    Europeans push IAEA Iran resolution despite warnings by Russia, Tehran    Kuwaiti cabinet proposes new amendments to debt law, MP says    Prince Philip to a London hospital for infection treatment    Beltone Financial Holding's loss widens 45% in 2020    Saudia plans to order 70 Airbus, Boeing jets: Report    FACTBOX: Key winners at the 2021 Golden Globes    EFG Hermes starts 3rd round of its Virtual Investor Conference    Live score: Wadi Degla v Zamalek (Egyptian Premier League)    Syria begins COVID-19 vaccinations with healthcare workers    Enhanced Labs signs Mr. Olympia 2020 "Big Ramy" And His Trainer Dennis James    Even more chaotic than usual, Golden Globes still had their moments    India's Mumbai City finish top, book Asian Champions League spot    EFG Hermes KSA completes advisory on Alkhorayef Water & Power Technologies' $ 144 mn IPO    Thousands flee rebel violence in Central African Republic    Aguero needs time to return to best form: Manchester City boss Guardiola    Netanyahu accuses Iran of attacking Israeli-owned cargo ship    State keen on completing Nile water quality improvement projects in 2 years: Egypt PM    Egyptian actress Ahlam El-Geretly dies at age 73    1st hours of registration for coronavirus vaccine seen 7,000 Egyptians signing up: ministry    Second coronavirus wave in Egypt more serious, widespread: statistics authority    Egypt lifts ban on Ramadan's Taraweeh prayers in some mosques coronavirus continues for a 2nd year    Egypt briefs Arab, European ambassadors on developments in GERD dispute    Eschewing the radical    Senate prepares for its first session    King Tutankhamun funerary mask is must-see tourist icon: The Telegraph    Russian flights to return to Sharm el-Sheikh and Hurghada for first time since 2015    Australia slams Facebook's move to block news as unnecessary and heavy-handed    Sisi calls on securing fair access to coronavirus vaccines for African nations    Egypt eyes gradual return for tourism after revenues fall to $4 bln in 2020    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    Coronavirus strikes Egypt's youth team as 17 players, coach test positive    Nassef Sawiris plans to up his stake in owner of New York Knicks, Rangers    Cairo International Book Fair suspended for five months over coronavirus concerns    Egypt, Ethiopia, Sudan to resume Nile dam talks today    Trump says won't blame Egypt for being ‘upset' over GERD dispute with Ethiopia    The Facebook Preacher's Search for Fame, and Egypt's Economy    Egypt calls on UNSC to address oil spill risks off Yemen coast    Egypt economically strong in face of COVID-19, reforms ongoing: International Cooperation Minister    Arafa Holding reports $144,000 COVID-19-related losses in April    Egypt's efforts in Libya to activate free will of Libyan people: Al-Sisi    Hyksos campaigns were internal takeover, not foreign invaders: study    COVID-19 affects Egypt sporting clubs    COVID-19 will soon turn to seasonal like swine flu: Presidential Health Advisor    ‘Egypt's Support' coalition convenes to discuss its Senate election list    Robbery attempt leads to discovery of Ptolemaic monuments in Qena    Flouting international guidance, Ethiopia unilaterally starts filling its Nile dam    Zaha speaks out after online racial abuse    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization
Published in Ahram Online on 18 - 11 - 2020

Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.
The drugmaker said efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world.
Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94%.
The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective. Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.
The better-than-expected data from the two vaccines, both developed with new technology known as messenger RNA (mRNA), have raised hopes for an end to a resurgent pandemic that has killed more than 1.3 million people globally and wreaked havoc upon economies and daily life.
However, while some groups such as healthcare workers will be prioritized in the United States for vaccinations this year, it will be months before large-scale rollouts begin.
Pfizer said on Wednesday there had been 170 cases of the disease in its trial of more 43,000 volunteers, of which 162 were observed in the placebo arm and 8 were in the vaccine group.
Ten people developed severe COVID-19, one of whom received the vaccine.
It also said the vaccine was well-tolerated and that side effects were mostly mild to moderate and cleared up quickly.
The only severe adverse event that affected more than 2% of those vaccinated was fatigue, which affected 3.7% of recipients after the second dose. Older adults tended to report fewer and milder solicited adverse events following vaccination.
The results come as the virus is running rampant in the United States, Europe and elsewhere, placing an enormous strain on healthcare systems with record numbers of new cases and hospitalizations.
The approach of winter in the northern hemisphere in tandem with the holiday season is expected to worsen case numbers as people spend more time indoors and get together for family gatherings.
"With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," Pfizer CEO Albert Bourla said in a statement.
Pfizer and BioNTech also said they plan to submit the data to other regulatory agencies around the world as well as the United States. They also plan to submit data from the study to a peer-reviewed scientific journal.
Pfizer reiterated it expects to make as many as 50 million vaccine doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.
Of the dozens of drugmakers and research groups racing to develop vaccines against COVID-19, the next data release will likely be from AstraZeneca Plc with the University of Oxford in November or December. Johnson & Johnson says it is on track to deliver data this year.


Clic here to read the story from its source.